IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of MICHAELIS, et al. Examiner:

Not Yet Assigned

Art Unit:

Application No.: Not Yet Known

Filed: Herewith

Title: THE USE OF ANTAGONISTS OF THE BRADYKININ B2 RECEPTOR FOR THE TREATMENT OF OSTEOARTHROSIS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are: :aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of the same aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of the same aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of the same aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of the same aware, which they believe may be material. this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

冈 (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

§1.113 in this
eign
0.5
ns prior
this
eign
е
٠
of this
er in
97(c) is
t e e

Respectfully submitted,

Jiang Lin, Reg. No. 51,065

Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0008 US NP

Please type a plus sign (+) inside this box	Patent and Tradem	PTO/SB/08A (10-96) oroved for use through 10/31/99. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	
Substitute for form 1449A/PTO	Complete if Known		
	Application Number	Not Yet Known	
INFORMATION DISCLOSURE	Filing Date	Herewith	
STATEMENT BY APPLICANT	First Named Inventor	MICHAELIS	
	Group Art Unit		
(use as many sheets as necessary)	Evaminer Name		

Examiner Name

Attorney Docket Number

DEAV2003/0008 - US - NP

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent Document Number Kind Code² (If known)		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		5648333			07-15-1997		
						<u> </u>	
		 					
		 			+		
		 		*			
		<u> </u>					
						**	
		ļ			 	 	
					+	· · · · · · · · · · · · · · · · · · ·	
						· · · · · · · · · · · · · · · · · · ·	
		ļ				· · · · · · · · · · · · · · · · · · ·	
					1		
			†				

				FO	REIGN PATENT	T DOCUMENT	S		
Examiner Initials	Cite No.1	Office	Foreign Patent Document Kind Code ³ Office ³ Number ⁴ (if known)		Annlicant of C	Patentee or Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
		EP	0472220		NESTOR, et a	l.	02-26-1992		
		<u> </u>						···	1
					-				+
		 	<u> </u>		 				╁
		-	 		 			<u>.</u>	+
					1.		i		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Sheet

1

of

2

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	lus sign (+) inside this	•		Patent and Tradem	PTO/SB/08B (10-96) proved for use through 10/31/99. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	
Substitute for form 1449B/PTO				Complete if Kn wn		
				Application Number	Not Yet Known	
INF	ORMATIO	N DI	SCLOSURE	Filing Date	Herewith	
STATEMENT BY APPLICANT				First Named Inventor	MICHAELIS	
				Group Art Unit		
	(use as many	sheets a	is necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	DEAV2003/0008 - US - NP	

	-	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), yolume-issue number(s)					
		MANICOURT, et al., Serum Levels Of Collagenase, Stromelysin-1, And Timp-1, Arthritis & Rheumatism, (1994), vol 37: 1774-1783					
	į						
-							
			*				
		•					
Examiner Signature		Date Considered					

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.